Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Globe Newswire•28/07/2026•07:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.